Insights into the occurrence and heterogeneity of gastric cancer from the perspective of clinical data integration

doi:10.12122/j.issn.1673-4254.2026.09.25

Abstract

Abstract:

From the perspective of clinical data integration, the authors systematically review recent advances in gastric cancer researches that integrate multi-omics technologies with clinical data. Gastric cancer is characterized by high incidence, high mortality, and significant heterogeneity, and this review analyzes the molecular classification system of gastric cancer and its driver genes by integrating multi-omics information-including genomics, transcriptomics, and proteomics-with clinical data, and further explores the mechanisms of interaction between cancer cells and stromal cells in the tumor microenvironment. On this basis, this review summarizes the clinical and molecular correlation patterns of different gastric cancer subtypes and constructs a comprehensive research framework that integrates clinical data, multi-omics networks, and the tumor microenvironment, thereby linking the mechanisms that drive the entire course of cancer progression from precancerous lesions to tumor advancement. This framework provides systematic theoretical support and a translational pathway for early prevention, screening, and precision diagnosis and treatment of gastric cancer, and contributes to the advancement of precision medicine in gastric cancer management.

Key words: gastric cancer, heterogeneity, genomic technology, proteome, transcriptome

Yafang HUANG, Simiao YANG, Xia DING, Fuhao CHU, Runhua CHEN. Insights into the occurrence and heterogeneity of gastric cancer from the perspective of clinical data integration[J]. Journal of Southern Medical University, 2026, 46(9): 2276-2284.

Figures/Tables 1

References 69

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2024, 74(3): 229-63. doi：10.3322/caac.21834
[2]	López MJ, Carbajal J, Alfaro AL, et al. Characteristics of gastric cancer around the world[J]. Crit Rev Oncol Hematol, 2023, 181: 103841. doi：10.1016/j.critrevonc.2022.103841
[3]	Hirata Y, Noorani A, Song SM, et al. Early stage gastric adenocarcinoma: clinical and molecular landscapes[J]. Nat Rev Clin Oncol, 2023, 20(7): 453-69. doi：10.1038/s41571-023-00767-w
[4]	Salvatori S, Marafini I, Laudisi F, et al. Helicobacter pylori and gastric cancer: pathogenetic mechanisms[J]. Int J Mol Sci, 2023, 24(3): 2895. doi：10.3390/ijms24032895
[5]	Goleij P, Heidari MM, Motevalli H, et al. Targeting the HGF/MET axis in cancer: therapeutic promise for natural compounds[J]. Eur J Med Chem, 2025, 298: 118027. doi：10.1016/j.ejmech.2025.118027
[6]	Su MC, Nethi SK, Dhanyamraju PK, et al. Nanomedicine strategies for targeting tumor stroma[J]. Cancers, 2023, 15(16): 4145. doi：10.3390/cancers15164145
[7]	Liu M, Liu Q, Zou Q, et al. The composition and roles of gastric stem cells in epithelial homeostasis, regeneration, and tumorigenesis[J]. Cell Oncol, 2023, 46(4): 867-83. doi：10.1007/s13402-023-00802-z
[8]	Li S, Gao J, Xu Q, et al. A signature-based classification of gastric cancer that stratifies tumor immunity and predicts responses to PD-1 inhibitors[J]. Front Immunol, 2021, 12: 693314. doi：10.3389/fimmu.2021.693314
[9]	Yuan QH, Deng DW, Pan C, et al. Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy[J]. Front Immunol, 2022, 13: 951137. doi：10.3389/fimmu.2022.951137
[10]	Zeng YJ, Jin RU. Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer[J]. Semin Cancer Biol, 2022, 86(Pt 3): 566-82. doi：10.1016/j.semcancer.2021.12.004
[11]	Norwood DA, Montalvan-Sanchez E, Dominguez RL, et al. Gastric cancer: emerging trends in prevention, diagnosis, and treatment[J]. Gastroenterol Clin North Am, 2022, 51(3): 501-18. doi：10.1016/j.gtc.2022.05.001
[12]	Wu XZ, Liu ZC, Qin XX, et al. The risk of incident gastric cancer for populations with different precancerous gastric lesions: a prospective follow-up study[J]. Zhonghua Liuxingbingxue Zazhi, 2022, 43(12): 1972-8.
[13]	Nie YZ, Gao XC, Cai XQ, et al. Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer[J]. Cancer Commun, 2023, 43(11): 1275-9. doi：10.1002/cac2.12478
[14]	Caliskan R, Sayi Yazgan A, Tokman HB, et al. The cytokine response in THP-1 (monocyte) and HL-60 (neutrophil-differentiated) cells infected with different genotypes of Helicobacter pylori strains[J]. Turk J Gastroenterol, 2015, 26(4): 297-303. doi：10.5152/tjg.2015.8058
[15]	Khazaaleh S, Alomari M, Rashid MU, et al. Gastric intestinal Metaplasia and gastric cancer prevention: Watchful waiting[J]. Cleve Clin J Med, 2024, 91(1): 33-9. doi：10.3949/ccjm.91a.23015
[16]	Ma YB, Jiang ZC, Pan LB, et al. Current development of molecular classifications of gastric cancer based on omics (Review)[J]. Int J Oncol, 2024, 65(3). DOI:10.3892/ijo.2024.5677 .
[17]	Nakajima S, Fukai S, Kaneta A, et al. Regulation of the tumor microenvironment through HER2 signaling-insights from gastric cancer cases with heterogeneous HER2 overexpression[J]. Gan To Kagaku Ryoho, 2024, 51(9): 903-5.
[18]	Shin M, Ahn S, Jung J, et al. Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer[J]. Cancer Med, 2023, 12(18): 18633-42. doi：10.1002/cam4.6472
[19]	Liu BL, Cleary JM, Shi J, et al. Claudin 18.2 and other therapeutic biomarkers in gastric and gastroesophageal junction adeno-carcinomas[J]. Am J Surg Pathol, 2025, 49(12): 1233-44. doi：10.1097/PAS.0000000000002464
[20]	Decourtye-Espiard L, Guilford P. Hereditary diffuse gastric cancer[J]. Gastroenterology, 2023, 164(5): 719-35. doi：10.1053/j.gastro.2023.01.038
[21]	Lu S, Duan RF, Cong L, et al. The effects of ARID1A mutation in gastric cancer and its significance for treatment[J]. Cancer Cell Int, 2023, 23(1): 296. doi：10.1186/s12935-023-03154-8
[22]	Dixon K, Brew T, Farnell D, et al. Modelling hereditary diffuse gastric cancer initiation using transgenic mouse-derived gastric organoids and single-cell sequencing[J]. J Pathol, 2021, 254(3): 254-64. doi：10.1002/path.5675
[23]	Benton D, Chernoff J. RHOA drivers take alternate routes in gastric cancer[J]. Sci Signal, 2023, 16(816): eadk9171. doi：10.1126/scisignal.adk9171
[24]	Estaji F, Zibaee S, Torabi M, et al. Epstein-Barr Virus and gastric carcinoma pathogenesis with emphasis on underlying epigenetic mechanisms[J]. Discov Oncol, 2024, 15(1): 719. doi：10.1007/s12672-024-01619-4
[25]	Singh AD, Gupta A, Mehta N, et al. Occurrence of gastric cancer in patients with juvenile polyposis syndrome: a systematic review and meta-analysis[J]. Gastrointest Endosc, 2023, 97(3): 407-14.e1. doi：10.1016/j.gie.2022.10.026
[26]	Wang HL, Guo M, Wei HD, et al. Targeting p53 pathways: mechanisms, structures, and advances in therapy[J]. Signal Transduct Target Ther, 2023, 8(1): 92. doi：10.1038/s41392-023-01347-1
[27]	Shi DK, Yang ZH, Cai YN, et al. Research advances in the molecular classification of gastric cancer[J]. Cell Oncol, 2024, 47(5): 1523-36. doi：10.1007/s13402-024-00951-9
[28]	Duan YT, Xu YH, Dou Y, et al. Helicobacter pylori and gastric cancer: mechanisms and new perspectives[J]. J Hematol Oncol, 2025, 18(1): 10. doi：10.1186/s13045-024-01654-2
[29]	Yeoh KG, Tan P. Mapping the genomic Diaspora of gastric cancer[J]. Nat Rev Cancer, 2022, 22(2): 71-84. doi：10.1038/s41568-021-00412-7
[30]	Wen JR, Deng SX, Bi YH, et al. Association between multiple gene promoter hypermethylation and the risk of gastric cancer: a systematic review and meta-analysis[J]. Dig Liver Dis, 2023, 55(1): 40-5. doi：10.1016/j.dld.2022.03.009
[31]	Shi Q, Xu GX, Jiang YL, et al. Phospholipase PLCE1 promotes transcription and phosphorylation of MCM7 to drive tumor progression in esophageal cancer[J]. Cancer Res, 2024, 84(4): 560-76. doi：10.1158/0008-5472.25224600
[32]	Zhang P, Yang MR, Zhang YD, et al. Dissecting the single-cell transcriptome network underlying gastric premalignant lesions and early gastric cancer[J]. Cell Rep, 2019, 27(6): 1934-47.e5. doi：10.1016/j.celrep.2019.04.052
[33]	Hatori S, Sakamaki K, Yokohori T, et al. Clinical significance of PLA2G2A expression in gastric cancer patients who receive gastrectomy and adjuvant S-1[J]. Anticancer Res, 2021, 41(7): 3583-8. doi：10.21873/anticanres.15146
[34]	Chen Y, Bai BJ, Ying KK, et al. Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(5): 188775. doi：10.1016/j.bbcan.2022.188775
[35]	Jeong HY, Ham IH, Lee SH, et al. Spatially distinct reprogramming of the tumor microenvironment based on tumor invasion in diffuse-type gastric cancers[J]. Clin Cancer Res, 2021, 27(23): 6529-42. doi：10.1158/1078-0432.ccr-21-0792
[36]	Zheng SW, Wang YY, Ni CX, et al. Helicobacter pylori SlyD stabilizes TPT1 via hnRNPK and enhances OCT1-mediated CDX2 transcriptional activation to drive gastric intestinal Metaplasia [J]. BMC Med, 2025, 23(1): 71. doi：10.1186/s12916-025-03911-8
[37]	Ma Q, Yang FF, Xiao B, et al. Emerging roles of circular RNAs in tumorigenesis, progression, and treatment of gastric cancer[J]. J Transl Med, 2024, 22(1): 207. doi：10.1186/s12967-024-05001-4
[38]	Yang ML, Zheng EK, Ni JJ, et al. Circular RNA circFOXO3 facilitate non-small cell lung cancer progression through upregulating HMGB3 via sponging miR-545-3p/miR-506-3p[J]. Tissue Cell, 2022, 75: 101702. doi：10.1016/j.tice.2021.101702
[39]	Ghafouri-Fard S, Honarmand Tamizkar K, Jamali E, et al. Contribution of circRNAs in gastric cancer[J]. Pathol Res Pract, 2021, 227: 153640. doi：10.1016/j.prp.2021.153640
[40]	Almalki WH, Almujri SS. The dual roles of circRNAs in Wnt/ β‑Catenin signaling and cancer progression[J]. Pathol Res Pract, 2024, 255: 155132. doi：10.1016/j.prp.2024.155132
[41]	Wang JJ, Zhang MX, Hu XH, et al. miRNA-194 predicts favorable prognosis in gastric cancer and inhibits gastric cancer cell growth by targeting CCND1[J]. FEBS Open Bio, 2021, 11(7): 1814-26. doi：10.1002/2211-5463.13125
[42]	Dos Santos EC, Rohan P, Binato R, et al. Integrated network analysis of microRNAs, mRNAs, and proteins reveals the regulatory interaction between hsa-mir-200b and CFL2 associated with advanced stage and poor prognosis in patients with intestinal gastric cancer[J]. Cancers, 2023, 15(22): 5374. doi：10.3390/cancers15225374
[43]	Xie ZL, Li JC, Huang P, et al. Applications and achievements of single-cell sequencing in gastrointestinal cancer[J]. Front Oncol, 2022, 12: 905571. doi：10.3389/fonc.2022.905571
[44]	Gilyazova I, Asadullina D, Kagirova E, et al. MiRNA-146a-a key player in immunity and diseases[J]. Int J Mol Sci, 2023, 24(16): 12767. doi：10.3390/ijms241612767
[45]	Lu JQ, Li D, Jiang HL, et al. The aryl sulfonamide indisulam inhibits gastric cancer cell migration by promoting the ubiquitination and degradation of the transcription factor ZEB1[J]. J Biol Chem, 2023, 299(4): 103025. doi：10.1016/j.jbc.2023.103025
[46]	Mahmoudzadeh-Sagheb A, Panahi M, Jami S, et al. Survivin as a potential biomarker for early diagnosis of the progression of precancerous lesions to gastric cancer[J]. Int J Biol Markers, 2024, 39(1): 52-8. doi：10.1177/03936155231217268
[47]	Shi WH, Wang YS, Xu C, et al. Multilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer[J]. Nat Commun, 2023, 14(1): 835. doi：10.1038/s41467-023-35797-6
[48]	Zhu XY, Chen H, Li H, et al. ITGB1-mediated molecular landscape and cuproptosis phenotype induced the worse prognosis in diffuse gastric cancer[J]. Front Oncol, 2023, 13: 1115510. doi：10.3389/fonc.2023.1115510
[49]	Zheng Z, Zhai YH, Yan XS, et al. Functions and clinical applications of exosomes in gastric cancer[J]. Int J Biol Sci, 2025, 21(5): 2330-45. doi：10.7150/ijbs.98087
[50]	Tanaka M. Crosstalk of tumor stromal cells orchestrates invasion and spreading of gastric cancer[J]. Pathol Int, 2022, 72(4): 219-33. doi：10.1111/pin.13211
[51]	Ramesh P, Nisar M, Neha, et al. Delineating protein biomarkers for gastric cancers: a catalogue of mass spectrometry-based markers and assessment of their suitability for targeted proteomics applications[J]. J Proteomics, 2024, 306: 105262. doi：10.1016/j.jprot.2024.105262
[52]	Soleimani A, Dadjoo P, Avan A, et al. Emerging roles of CD133 in the treatment of gastric cancer, a novel stem cell biomarker and beyond[J]. Life Sci, 2022, 293: 120050. doi：10.1016/j.lfs.2021.120050
[53]	Koelsch N, Manjili MH. From reductionistic approach to systems immunology approach for the understanding of tumor microenvironment[J]. Int J Mol Sci, 2023, 24(15): 12086. doi：10.3390/ijms241512086
[54]	Bian SH, Wang YC, Zhou Y, et al. Integrative single-cell multiomics analyses dissect molecular signatures of intratumoral hetero-geneities and differentiation states of human gastric cancer[J]. Natl Sci Rev, 2023, 10(6): nwad094. doi：10.1093/nsr/nwad094
[55]	Zhang XJ, Ren B, Liu B, et al. Single-cell RNA sequencing and spatial transcriptomics reveal the heterogeneity and intercellular communication of cancer-associated fibroblasts in gastric cancer[J]. J Transl Med, 2025, 23(1): 344. doi：10.1186/s12967-025-06376-8
[56]	Song JQ, Wei RY, Liu CC, et al. Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response[J]. Nat Commun, 2025, 16(1): 2175. doi：10.1038/s41467-025-57465-7
[57]	Xu L, Li K, Li J, et al. IL-18 serves as a main effector of CAF-derived METTL3 against immunosuppression of NSCLC via driving NF-κB pathway[J]. Epigenetics, 2023, 18(1): 2265625. doi：10.1080/15592294.2023.2265625
[58]	Choi KM, Kim B, Lee SM, et al. Characterization of gastric cancer-stimulated signaling pathways and function of CTGF in cancer-associated fibroblasts[J]. Cell Commun Signal, 2024, 22(1): 8. doi：10.1186/s12964-023-01396-7
[59]	Li XC, Sun Z, Peng GX, et al. Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer[J]. Theranostics, 2022, 12(2): 620-38. doi：10.7150/thno.60540
[60]	Wang QY, Chen J, Wang YH, et al. The profiles of immunosuppressive microenvironment in the Lauren intestinal-type gastric adenocarcinoma[J]. Cancer Immunol Immunother, 2025, 74(3): 82. doi：10.1007/s00262-024-03938-5
[61]	Zhou L, Yang M, Deng C, et al. Single-cell sequencing reveals the role of IL-33 (+) endothelial subsets in promoting early gastric cancer progression[J]. Imeta, 2025, 4(4): e70050. doi：10.1002/imt2.70050
[62]	Ma HR, Srivastava S, Ho SWT, et al. Spatially resolved tumor ecosystems and cell states in gastric adenocarcinoma progression and evolution[J]. Cancer Discov, 2025, 15(4): 767-92. doi：10.1158/2159-8290.cd-24-0605
[63]	He YX, Wang JY, Deng ZL, et al. FOLR2(+) macrophage depletion from intestinal Metaplasia to early gastric cancer: single-cell sequencing insight into gastric cancer progression[J]. J Exp Clin Cancer Res, 2024, 43(1): 326. doi：10.1186/s13046-024-03245-y
[64]	Ji CG, Cai HM, Jin XX, et al. Identification of immune infiltrating cell-related biomarkers in early gastric cancer progression[J]. Technol Cancer Res Treat, 2024, 23: 15330338241262724. doi：10.1177/15330338241262724
[65]	Wang JY, Zhang H, Li JT, et al. Exosome-derived proteins in gastric cancer progression, drug resistance, and immune response[J]. Cell Mol Biol Lett, 2024, 29(1): 157. doi：10.1186/s11658-024-00676-5
[66]	Li NS, Chen SH, Xu XB, et al. Single-cell transcriptomic profiling uncovers cellular complexity and microenvironment in gastric tumorigenesis associated with Helicobacter pylori [J]. J Adv Res, 2025, 74: 471-91. doi：10.1016/j.jare.2024.10.012
[67]	Zheng LT, Qin SS, Si W, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells[J]. Science, 2021, 374(6574): abe6474. doi：10.1126/science.abe6474
[68]	Kang BX, Camps J, Fan B, et al. Parallel single-cell and bulk transcriptome analyses reveal key features of the gastric tumor microenvironment[J]. Genome Biol, 2022, 23(1): 265. doi：10.1186/s13059-022-02828-2
[69]	Wu J, Zhang PF, Zeng Y, et al. Effects of FAP(+) cancer-associated fibroblasts on anti-PD-1 immunotherapy and CD4⁺ T cell polari-zation in gastric cancer[J]. Cancer Drug Resist, 2025, 8: 38. doi：10.20517/cdr.2025.97